mProX™ Human SSTR5 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Sabrina
Verified Customer
Conrad
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 Epigenetic regulation mechanisms of inactivation of SSTR5 and SSTR5-AS1 in LSCC.
In laryngeal cancer cells treated or not treated with 5-Aza-dC, the BS-MSP analysis was used to determine the degree of methylation in the promoter and exon 1 regions of SSTR5. SSTR5's relative expression levels in tumor tissues with and without promoter and exon 1 methylation.
Ref: Wang, Baoshan, et al. "Aberrant methylation-mediated downregulation of lncRNA SSTR5-AS1 promotes progression and metastasis of laryngeal squamous cell carcinoma." Epigenetics & Chromatin 12.1 (2019): 1-17.
Pubmed: 31196171
DOI: 10.1186/s13072-019-0283-8
Research Highlights
In comparison to previously reported drugs, this study discovered new SSTR5 antagonists with improved potency, subtype selectivity, and negligible off-target effects.
Liu, Weiguo, et al. "Discovery and pharmacology of a novel somatostatin subtype 5 (SSTR5) antagonist: synergy with DPP-4 inhibition." ACS Medicinal Chemistry Letters 9.11 (2018): 1082-1087.
Pubmed:
30429949
DOI:
10.1021/acsmedchemlett.8b00305
Treatment that targets the somatostatin receptors (SSTRs) may be beneficial for the rare tumors known as neuroendocrine breast cancer (NEBC). Given their continuous expression in primary and metastatic gastro-intestinal and pancreatic neuroendocrine tumors, SSTR2A and SSTR5 in particular are prospective targets.
Terlević, Robert, et al. "Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer." Annals of Diagnostic Pathology 38 (2019): 62-66.
Pubmed:
30476894
DOI:
10.1016/j.anndiagpath.2018.11.002
